Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04926155 | The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 234 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT04918628 | Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer(CRTCP) | unknown | Phase 2 | 50 | Taizhou HospitalOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04836663 | A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors | unknown | Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04395612 | Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer(CQGOG0101) | unknown | Phase 2 | 38 | Chongqing University Cancer HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | unknown | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04556539 | Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer | unknown | Phase 2 | 104 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 12, 2021 | clinicaltrials |
| NCT00703105 | Ovarian Dendritic Cell Vaccine Trial | unknown | Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04828616 | Study of DP303c Injection in Patients With Advanced Ovarian Cancer | unknown | Phase 2 | 104 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04815408 | PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer | unknown | Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 25, 2021 | clinicaltrials |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04800978 | Combination of Durvalumab and BVAC-C in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 0 | Mar 16, 2021 | clinicaltrials |
| NCT04789941 | How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix | unknown | Phase 2 | 50 | Assiut UniversityOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT03808857 | A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive | unknown | Phase 2 | 80 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Mar 3, 2021 | clinicaltrials |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)(CaboPen) | unknown | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT02944201 | Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate | unknown | Phase 2 | 22 | Montefiore Medical CenterOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04736108 | Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 50 | West China HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer(CLIO) | unknown | Phase 2 | 160 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03432780 | Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer(QRT-SOGUG) | unknown | Phase 2 | 134 | Spanish Oncology Genito-Urinary GroupOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04622761 | Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome(CHROME) | unknown | Phase 2 | 120 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT04664244 | Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | unknown | Phase 2 | 43 | Lei LiOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01835977 | Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer | unknown | Phase 2 | 106 | Clinical Research Office of the Endourological SocietyOTHER | 0 | Dec 16, 2020 | clinicaltrials |
| NCT04661696 | Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. | unknown | Phase 2 | 75 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT04651946 | Cell-free DNA Methylation for Epithelial Ovarian Cancer | unknown | Phase 2 | 400 | Lei LiOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04376073 | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer(ANNIE) | unknown | Phase 2 | 40 | Jihong LiuOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT01505075 | Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer(pHART8) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01953055 | SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)(SATURN) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03307460 | uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness | unknown | Phase 2 | 52 | Rigshospitalet, DenmarkOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT04635956 | Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04566952 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer(ANLOLA) | unknown | Phase 2 | 68 | Xiaoxiang ChenOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04590625 | Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | unknown | Phase 2 | 58 | Zhongshan Hospital Xiamen UniversityOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03899610 | A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)(KGOG3046) | unknown | Phase 2 | 24 | Yonsei UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT02282137 | 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer(PSMA) | unknown | Phase 2 | 208 | Ebrahim DelpassandOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT03295526 | Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer | unknown | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04504110 | 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04489745 | Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer | unknown | Phase 2 | 72 | VA Greater Los Angeles Healthcare SystemFED | 0 | Jul 28, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03506997 | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer(PERSEUS1) | unknown | Phase 2 | 100 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02742675 | Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | unknown | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03380806 | Prostate Boost Irradiation With Stereotactic Body RT (SBRT)(PBS) | unknown | Phase 2 | 100 | Juravinski Cancer CenterOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT04073680 | A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Petra PharmaINDUSTRY | 0 | May 21, 2020 | clinicaltrials |
| NCT02691975 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 197 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 13, 2020 | clinicaltrials |
| NCT04383977 | Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 12, 2020 | clinicaltrials |
| NCT04368273 | Pd-1 Antibody Combined CCRT for Local Advanced Cervical Cancer.(CCRT+PD-1) | unknown | Phase 1 / Phase 2 | 30 | Peking University Third HospitalOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT04310774 | CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer | unknown | Phase 1 / Phase 2 | 200 | Peking Union Medical College HospitalOTHER | 0 | Mar 19, 2020 | clinicaltrials |
| NCT04261465 | NUVOLA TRIAL Open-label Multicentre Study(NUVOLA) | unknown | Phase 2 | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 14, 2021source: clinicaltrials